본문 바로가기
KERD
논문KCI 등재

Heart failure with preserved ejection fraction: insights from recent clinical researches

Seong-Mi Park|Mi-Na Kim
대한내과학회 (The Korean Association Of Internal Medicine)|2020.05|The Korean Journal of Internal Medicine|제35권 제3호|pp. 514-534|DOI https://doi.org/10.3904/kjim.2020.104

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

TherapyHeart failurePreserved ejection fraction
주제분류내과학

초록

Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of HF and its incidence might be increasing with the aging society. Patients with HFpEF present with significant symptoms, including exercise intolerance, impaired quality of life, and have a poor prognosis as well as frequent hospitalization and increased mortality compared with HF with reduced ejection fraction. The concept of HFpEF is still evolving and may be a virtual complex rather than a real systemic disorder. Thus, beyond solely targeting cardiac abnormalities management strategies need to be extended, such as left ventricular diastolic dysfunction. In this review, we examine new diagnostic algorithms, pathophysiology, current management status, and ongoing trials based on heterogeneous pathophysiology and etiology in HFpEF.

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of HF and its incidence might be increasing with the aging society. Patients with HFpEF present with significant symptoms, including exercise intolerance, impaired quality of life, and have a poor prognosis as well as frequent hospitalization and increased mortality compared with HF with reduced ejection fraction. The concept of HFpEF is still evolving and may be a virtual complex rather than a real systemic disorder. Thus, beyond solely targeting cardiac abnormalities management strategies need to be extended, such as left ventricular diastolic dysfunction. In this review, we examine new diagnostic algorithms, pathophysiology, current management status, and ongoing trials based on heterogeneous pathophysiology and etiology in HFpEF.

참고문헌 (117)

  1. Kitzman DW, "Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study", Am J Cardiol, 87, pp.413~419 (2001)
  2. Heidenreich PA, "Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association", Circ Heart Fail, 6, pp.606~619 (2013)
  3. Chamberlain AM, "Burden and timing of hospitalizations in heart failure : a community study", Mayo Clin Proc, 92, pp.184~192 (2017)
  4. Fonarow GC, "Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure : a report from the OPTIMIZE-HF Registry", J Am Coll Cardiol, 50, pp.768~777 (2007)
  5. Shah SJ, "Phenotype-specific treatment of heart failure with preserved ejection fraction : a multiorgan roadmap", Circulation, 134, pp.73~90 (2016)
  6. Upadhya B, "Heart failure with preserved ejection fraction : new approaches to diagnosis and management", Clin Cardiol, 43, pp.145~155 (2020)
  7. 김민석, "Korean Guidelines for Diagnosis and Management of Chronic Heart Failure", Korean Circulation Journal, 47(5), pp.555~643 (2017), 대한심장학회[DOI]
  8. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
  9. Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
  10. Michaud M, "Patients with high left ventricular filling pressure may be missed applying 2016 echo guidelines : a pilot study", Int J Cardiovasc Imaging, 35, pp.2157~2166 (2019)
  11. Richards AM, "N-terminal B-type natriuretic peptide in heart failure", Heart Fail Clin, 14, pp.27~39 (2018)
  12. Abergel E, "Evaluation of left ventricular filling pressure : Updated recommendations lack new evidence and have severe interpretation issues", Arch Cardiovasc Dis, 111, pp.707~711 (2018)
  13. Vaduganathan M, "Prior heart failure hospitalization, clinical outcomes, and response to sacubitril", valsartan compared with valsartan in HFpEF, 2020, pp.75, 245~254
  14. Reddy YNV, "A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction", Circulation, 138, pp.861~870 (2018)
  15. Pieske B, "How to diagnose heart failure with preserved ejection fraction: the HFAPEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)", Eur Heart J, 40, pp.3297~3317 (2019)
  16. Segar MW, "Generalizability and implications of the H<sub>2<", sub>FPEF score in a cohort of patients with heart failure with preserved ejection fraction, 2019, pp.139, 1851~1853
  17. Sueta D, "H2FPEF score as a prognostic value in HFpEF patients", Am J Hypertens, 32, pp.1082~1090 (2019)
  18. Barandiaran Aizpurua A, "Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction", Eur J Heart Fail, 22, pp.413~421 (2020)
  19. Mohammed SF, "Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction : a community-based study", Circ Heart Fail, 5, pp.710~719 (2012)
  20. Zakeri R, "Heart failure with preserved ejection fraction : controversies, challenges and future directions", Heart, 104, pp.377~384 (2018)
  21. Pfeffer MA, "Heart failure with preserved ejection fraction in perspective", Circ Res, 124, pp.1598~1617 (2019)
  22. Gevaert AB, "Heart failure with preserved ejection fraction : a review of cardiac and noncardiac pathophysiology", Front Physiol, 10, pp.638~ (2019)
  23. Franssen C, "Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction", JACC Heart Fail, 4, pp.312~324 (2016)
  24. Zile MR, "Myocardial stiffness in patients with heart failure and a preserved ejection fraction : contributions of collagen and titin", Circulation, 131, pp.1247~1259 (2015)
  25. Westermann D, "Role of left ventricular stiffness in heart failure with normal ejection fraction", Circulation, 117, pp.2051~2060 (2008)
  26. Borlaug BA, "Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction", Heart, 97, pp.964~969 (2011)
  27. Borlaug BA, "Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction", Eur Heart J, 37, pp.3293~3302 (2016)
  28. Melenovsky V, "Lung congestion in chronic heart failure : haemodynamic, clinical, and prognostic implications", Eur J Heart Fail, 17, pp.1161~1671 (2015)
  29. Obokata M, "Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction", Eur Heart J, 39, pp.2810~2821 (2018)
  30. Dorfs S, "Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction", Eur Heart J, 35, pp.3103~3112 (2014)
  31. Melenovsky V, "Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction", Circ Heart Fail, 8, pp.295~303 (2015)
  32. Reddy YNV, "The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction", Eur Heart J, 40, pp.3721~3730 (2019)
  33. Telles F, "Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction", Eur J Heart Fail, 21, pp.495~505 (2019)
  34. Khan MS, "Left atrial function in heart failure with preserved ejection fraction : a systematic review and meta-analysis", Eur J Heart Fail, 22, pp.472~485 (2020)
  35. Patel RB, "Therapeutic targeting of left atrial myopathy in atrial fibrillation and heart failure with preserved ejection fraction", JAMA Cardiol (2020)[DOI]
  36. Vanderpool RR, "Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction", JAMA Cardiol, 3, pp.298~306 (2018)
  37. Andersen MJ, "Enhanced pulmonary vasodilator reserve and abnormal right ventricular : pulmonary artery coupling in heart failure with preserved ejection fraction", Circ Heart Fail, 8, pp.542~550 (2015)
  38. Gorter TM, "Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease", Eur Heart J, 39, pp.2825~2835 (2018)
  39. Obokata M, "Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction", Eur Heart J, 40, pp.689~697 (2019)
  40. Obokata M, "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction", Circulation, 136, pp.6~19 (2017)
  41. Tan YT, "The pathophysiology of heart failure with normal ejection fraction : exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion", J Am Coll Cardiol, 54, pp.36~46 (2009)
  42. Shah AM, "Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone", Circulation, 132, pp.402~414 (2015)
  43. Abudiab MM, "Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction", Eur J Heart Fail, 15, pp.776~785 (2013)
  44. Potter E, "Assessment of left ventricular function by echocardiography : the case for routinely adding global longitudinal strain to ejection fraction", JACC Cardiovasc Imaging, 11, pp.260~274 (2018)
  45. Herscovici R, "Ischemia and no obstructive coronary artery disease(INOCA) : what is the risk", J Am Heart Assoc, 7, pp.e008868~ (2018)
  46. Elgendy IY, "Heart failure with preserved ejection fraction : is ischemia due to coronary microvascular dysfunction a mechanistic factor", Am J Med, 132, pp.692~697 (2019)
  47. Murthy VL, "Effects of sex on coronary microvascular dysfunction and cardiac outcomes", Circulation, 129, pp.2518~2527 (2014)
  48. Taqueti VR, "Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction", Eur Heart J, 39, pp.840~849 (2018)
  49. Shah SJ, "Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction : PROMIS-HFpEF", Eur Heart J, 39, pp.3439~3450 (2018)
  50. Park SM, "Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study", Eur Heart J Cardiovasc Imaging, 20, pp.875~882 (2019)
  51. Haykowsky MJ, "Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction : role of lean body mass", J Gerontol A Biol Sci Med Sci, 68, pp.968~975 (2013)
  52. Heinonen I, "Regulation of subcutaneous adipose tissue blood flow during exercise in humans", J Appl Physiol(1985), 112, pp.1059~1063 (2012)
  53. Kitzman DW, "Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction", Am J Physiol Heart Circ Physiol, 306, pp.H1364~H1370 (2014)
  54. Molina AJ, "Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance", JACC Heart Fail, 4, pp.636~645 (2016)
  55. Jia G, "Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness", Hypertension, 72, pp.537~548 (2018)
  56. Pugliese NR, "The renin-angiotensin-aldosterone system : a crossroad from arterial hypertension to heart failure", Heart Fail Rev, 25, pp.31~42 (2020)
  57. Cabandugama PK, "The renin angiotensin aldosterone system in obesity and hypertension : roles in the cardiorenal metabolic syndrome", Med Clin North Am, 101, pp.129~137 (2017)
  58. Seccia TM, "Atrial fibrillation and arterial hypertension : a common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role", Int J Cardiol, 206, pp.71~76 (2016)
  59. Yusuf S, "Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial", Lancet, 362, pp.777~781 (2003)
  60. Cleland JG, "The perindopril in elderly people with chronic heart failure(PEP-CHF)study", Eur Heart J, 27, pp.2338~2345 (2006)
  61. Massie BM, "Irbesartan in patients with heart failure and preserved ejection fraction", N Engl J Med, 359, pp.2456~2467 (2008)
  62. Pitt B, "Spironolactone for heart failure with preserved ejection fraction", N Engl J Med, 370, pp.1383~1392 (2014)
  63. Pfeffer MA, "Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial", Circulation, 131, pp.34~42 (2015)
  64. de Denus S, "Spironolactone metabolites in TOPCAT : new insights into regional variation", N Engl J Med, 376, pp.1690~1692 (2017)
  65. Solomon SD, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial", Lancet, 380, pp.1387~1395 (2012)
  66. Solomon SD, "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction", N Engl J Med, 381, pp.1609~1620 (2019)
  67. McMurray JJV, "Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction : insights from PARAGON-HF", Circulation, 141, pp.338~351 (2020)
  68. Solomon SD, "Sacubitril", valsartan across the spectrum of ejection fraction in heart failure, 2020, pp.141, 352~361
  69. McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
  70. Koh AS, "A comprehensive population-based characterization of heart failure with midrange ejection fraction", Eur J Heart Fail, 19, pp.1624~1634 (2017)
  71. Kuno T, "Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction", Am J Cardiol, 125, pp.1187~1193 (2020)
  72. Chatterjee S, "Benefits of β blockers in patients with heart failure and reduced ejection fraction : network meta-analysis. Version 2", BMJ, 346, pp.f55~ (2013)
  73. Lam PH, "Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction", J Am Coll Cardiol, 70, pp.1861~1871 (2017)
  74. Shah R, "Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function", Am J Cardiol, 101, pp.217~222 (2008)
  75. Gomez-Soto FM, "Mortality and morbidity of newly diagnosed heart failure with preserved systolic function treated with β-blockers : a propensity-adjusted case-control populational study", Int J Cardiol, 146, pp.51~55 (2011)
  76. Yanagihara K, "Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction", J Cardiovasc Pharmacol, 62, pp.485~490 (2013)
  77. van Veldhuisen DJ, "Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction : data from SENIORS(Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)", J Am Coll Cardiol, 53, pp.2150~2158 (2009)
  78. Yamamoto K, "Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study(J-DHF)", Eur J Heart Fail, 15, pp.110~118 (2013)
  79. Bavishi C, "Beta-blockers in heart failure with preserved ejection fraction : a meta-analysis", Heart Fail Rev, 20, pp.193~201 (2015)
  80. Martin N, "Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction", Cochrane Database Syst Rev, 6, pp.CD012721~ (2018)
  81. Liu F, "Effects of beta-blockers on heart failure with preserved ejection fraction : a meta-analysis", PLoS One, 9, pp.e90555~ (2014)
  82. Silverman DN, "Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction : a secondary analysis of the TOPCAT trial", JAMA Netw Open, 2, pp.e1916598~ (2019)
  83. Williams B, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes : principal results of the Conduit Artery Function Evaluation(CAFE)study", Circulation, 113, pp.1213~1225 (2006)
  84. Meyer M, "Heart rate and heart failure with preserved ejection fraction : time to slow β-blocker use", Circ Heart Fail, 12, pp.e006213~ (2019)
  85. Sung-Hwan Kim, "Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry", Korean Circulation Journal, 49(3), pp.238~248 (2019), 대한심장학회[DOI]
  86. Park JJ, "Myocardial strain for identification of β-blocker responders in heart failure with preserved ejection fraction", J Am Soc Echocardiogr, 32, pp.1462~1469 (2019)
  87. Jae Yeong Cho, "Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?", Korean Circulation Journal, 49(3), pp.249~251 (2019), 대한심장학회[DOI]
  88. Redfield MM, "Isosorbide mononitrate in heart failure with preserved ejection fraction", N Engl J Med, 373, pp.2314~2324 (2015)
  89. Schwartzenberg S, "Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy", J Am Coll Cardiol, 59, pp.442~451 (2012)
  90. Upadhya B, "Therapy for heart failure with preserved ejection fraction : current status, unique challenges, and future directions", Heart Fail Rev, 23, pp.609~629 (2018)
  91. Chirinos JA, "The nitrate-nitrite-NO pathway and its implications for heart failure and preserved ejection fraction", Curr Heart Fail Rep, 13, pp.47~59 (2016)
  92. Eggebeen J, "One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction", JACC Heart Fail, 4, pp.428~437 (2016)
  93. Shaltout HA, "Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and", or heart failure with preserved ejection fraction, 2017, pp.69, 78~90
  94. Borlaug BA, "Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction : the INDIE-HFpEF randomized clinical trial", JAMA, 320, pp.1764~1773 (2018)
  95. Bonderman D, "Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure(DILATE-1) : a randomized, double-blind, placebo-controlled, single-dose study", Chest, 146, pp.1274~1285 (2014)
  96. Pieske B, "Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction : results of the SOluble guanylate Cyclase stimulatoR in heart failurE patientS with PRESERVED EF(SOCRATES-PRESERVED)study", Eur Heart J, 38, pp.1119~1127 (2017)
  97. Zhuang XD, "PDE5inhibitor sildenafil in the treatment of heart failure : a meta-analysis of randomized controlled trials", Int J Cardiol, 172, pp.581~587 (2014)
  98. Hussain I, "Impaired right ventricular-pulmonary arterial coupling and effect of sildenafil in heart failure with preserved ejection fraction:an ancillary analysis from the phosphodiesterase-5inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial", Circ Heart Fail, 9, pp.e002729~ (2016)
  99. Liu LC, "Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension", Eur J Heart Fail, 19, pp.116~125 (2017)
  100. Abraham WT, "Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial", Lancet, 377, pp.658~666 (2011)
  101. Adamson PB, "Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction", Circ Heart Fail, 7, pp.935~944 (2014)
  102. Desai AS, "Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice", J Am Coll Cardiol, 69, pp.2357~2365 (2017)
  103. Hasenfub G, "A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial", Lancet, 387, pp.1298~1304 (2016)
  104. ): a phase 2, randomized, sham-controlled trial, "Circulation", 2018, 364~375
  105. Shah SJ, "One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure(REDUCE LAPHF I)trial : a randomized clinical trial", JAMA Cardiol, 3, pp.968~977 (2018)
  106. Kjeldsen SE, "Medical therapies for heart failure with preserved ejection fraction", Hypertension, 75, pp.23~32 (2020)
  107. Kawano H, "Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction : a systematic review and meta-analysis", Hypertens Res, 42, pp.504~513 (2019)
  108. Stewart Coats AJ, "Common co-morbidities in heart failure : diabetes, functional mitral regurgitation and sleep apnoea", Int J Heart Fail, 1, pp.25~41 (2019)
  109. McMurray JJV, "Dapagliflozin in patients with heart failure and reduced ejection fraction", N Engl J Med, 381, pp.1995~2008 (2019)
  110. Lan NSR, "The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function : current evidence and future directions", ESC Heart Fail, 6, pp.927~935 (2019)
  111. Kato ET, "Sodium-glucose co-transporters-2inhibitors and heart failure : state of the art review and future potentials", Int J Heart Fail, 2, pp.12~22 (2020)
  112. Soga F, "Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure", Cardiovasc Diabetol, 17, pp.132~ (2018)
  113. Pabel S, "Empagliflozin directly improves diastolic function in human heart failure", Eur J Heart Fail, 20, pp.1690~1700 (2018)
  114. Aggarwal M, "Lifestyle modifications for preventing and treating heart failure", J Am Coll Cardiol, 72, pp.2391~2405 (2018)
  115. Edelmann F, "Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction : results of the Ex-DHF(Exercise training in Diastolic Heart Failure)pilot study", J Am Coll Cardiol, 58, pp.1780~1791 (2011)
  116. Kitzman DW, "Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction : a randomized, controlled, single-blind trial", J Am Coll Cardiol, 62, pp.584~592 (2013)
  117. Kitzman DW, "Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction : a randomized clinical trial", JAMA, 315, pp.36~46 (2016)

관련 논문AI추천

Breakthrough in heart failure with preserved ejection fraction: are we there yet?Carolyn Su Ping Lam, Shir Lynn Lim대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제1호Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges정미향, Mi-Seung Shin대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제2호HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fractionDaisuke Sueta, Eiichiro Yamamoto, Fumi Oike, Hirofumi Soejima, Hiroki Usuku, Kenichi Matsushita, Kenichi Tsujita, Kenshi Yamanaga, Koichi Egashira, Koichi Kaikita, Koichiro Fujisue, Masafumi Takae, Miwa Ito, Satoshi Araki, Seiji Takashio, Shinsuke Hanatani, Taiki Nishihara, Takanori Tokitsu, Takashi Komorita대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제1호Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective하종원, Jae K. Oh한국심초음파학회 · Journal of Cardiovascular Imaging2009 · 제17권 제3호심장의 이완 기능의 평가 및 박출률 보존 심부전에서의 역할허란대한내과학회 · 대한내과학회지2022 · 제97권 제6호Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatmentByung-Su Yoo, Se-Eun Kim대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제3호

이 간행물의 다른 논문 (27건)

Current status of heart failure: global and KoreaDong-Ju Choi, Jin Joo Parkpp. 487-497Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidenceHong-Mi Choi, Mi-Seung Shinpp. 498-513Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with rectal non-steroidal anti-inflammatory drugsTae Young Park, Hyoung-Chul Oh, Evan L. Fogel, Glen A. Lehmanpp. 535-543Is serum pepsinogen testing necessary in populationbased screening for gastric cancer?Yeon-Ji Kim, Woo Chul Chungpp. 544-546We can do much better than what we did이상학pp. 547-549
원문 보기